Analysts Are Very Bullish About Heartflow (HTFL) Stock. Here’s Why
Heartflow Inc. (NASDAQ:HTFL) hit a new all-time high, rising to $42.99 and closing at $42.08, up 35.7%. The company reported Q2 revenue up 48% to $64.08M. Net loss widened to $15.7M. Full-year revenue growth guidance was raised to 40-42% ($246M-$250M). Analysts at Stifel, JPMorgan, and Wells Fargo raised price targets.
How this was made
The 30-second read
Why it matters
The key tradable change is the raised full-year revenue growth outlook (from 29% to 32% to 40% to 42%) alongside a Q2 revenue beat, which can reset expectations for FY estimates and near-term momentum.
Market read
Guidance raise plus Q2 revenue strength is a direct expectation reset for HTFL, while widening net loss introduces a counterweight for risk management.
What to watch
Investors may focus on gross margin and operating leverage claims, but the article provides no new cost breakdown or cash-flow detail to validate a path to durable profitability.
Background
Heartflow is an AI diagnostic company for coronary artery disease, with revenue tied to its US Fractional Flow Reserve (FFR) and Plaque offerings.
Ticker impact
Heartflow reported Q2 revenue up 48% to $64.08M and raised full-year revenue growth guidance to 40% to 42% ($246M to $250M).
Bias toward continued strength or volatility as traders weigh guidance upside versus larger net losses.
The article discloses a concrete guidance raise and Q2 revenue beat, which are direct drivers for valuation and expectations, while also noting a larger net loss that can cap enthusiasm.
Market effects
Positive read-through for CAD diagnostic and AI-medtech peers if investors rotate into under-penetrated cardiology platforms.
Primarily US small-cap growth sentiment, with limited direct regional spillover beyond healthcare tech.
Modest global relevance, as the disclosed catalysts are company-specific and US-focused (US FFR and Plaque revenue).
Counterpoint
The guidance raise may be driven by revenue volume growth while profitability deteriorates, so the stock’s multiple could compress if losses keep widening.
Key entities
- companyHeartflow Inc.
NASDAQ-listed AI diagnostic company for coronary artery disease; reported Q2 revenue growth and raised FY guidance.
- executiveJohn Farquhar
CEO and President, cited commentary on category leadership, under-penetration, and scalability.
- analyst_firmStifel
Raised price target to $45 and maintained buy rating after Q2 revenue beat.
- analyst_firmJPMorgan
Raised price target to $45 from $35 and maintained overweight rating.
- analyst_firmWells Fargo
Upgraded price target to $39 from $37, citing potential upside versus guidance.
